Walter Fitzhugh
Addiction Medicine · Lincoln, RINPI 1518973148
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.1% of the total across 312 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 44.2% of the total. Reporting peaked in 2019 at $2,006 and has fallen 90.4% since, to $192 in 2024.
Across 312 payments — averaging $16.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Takeda Pharmaceuticals U.S.A., Inc.$796
- Teva Pharmaceuticals USA, Inc.$305
- Sunovion Pharmaceuticals Inc.$275
- Shire North American Group Inc$253
- Lundbeck LLC$206
- plus $948 from 13 others
What the payments were for
- Food & beverage$4,80096%
- Education$1934%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 145 | $2,209 |
| Takeda Pharmaceuticals U.S.A., Inc. | 42 | $796 |
| Teva Pharmaceuticals USA, Inc. | 10 | $305 |
| Sunovion Pharmaceuticals Inc. | 20 | $275 |
| Shire North American Group Inc | 28 | $253 |
| Lundbeck LLC | 12 | $206 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $145 |
| Jazz Pharmaceuticals Inc. | 6 | $139 |
| Avanir Pharmaceuticals, Inc. | 6 | $115 |
| Corium, LLC | 13 | $101 |
| Vanda Pharmaceuticals Inc. | 4 | $96 |
| Otsuka America Pharmaceutical, Inc. | 5 | $86 |
| Neurocrine Biosciences, Inc. | 4 | $72 |
| Johnson & Johnson | 2 | $45 |
| Ironshore Pharmaceuticals Inc. | 3 | $45 |
| Neos Therapeutics, LP | 2 | $39 |
| Axsome Therapeutics, Inc. | 2 | $37 |
| Alkermes, Inc. | 1 | $15 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
How this compares
Too few addiction medicine providers in Rhode Islandto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 21 | $29,160 |
| Risperdal ConstaRisperidone Microspheres | 21 | $27,900 |
| TrintellixVortioxetine Hydrobromide | 39 | $20,662 |
| SeroquelQuetiapine Fumarate | 12 | $6,529 |
| Quetiapine Fumarate | 157 | $3,751 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 86 | $3,432 |
| Trazodone Hcl | 221 | $2,503 |
| Bupropion Hcl SrBupropion Hcl | 169 | $2,261 |
| Clonazepam | 242 | $2,232 |
| Sertraline Hcl | 194 | $2,232 |
| Divalproex Sodium ErDivalproex Sodium | 35 | $2,182 |
| Escitalopram Oxalate | 159 | $2,101 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 73 | $2,090 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 19 | $1,940 |
| Duloxetine Hcl | 48 | $1,907 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $2,209 | $29,16021 claims |
| Johnson & JohnsonRisperdal Consta | $45 | $27,90021 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $796 | $20,66239 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few addiction medicine providers in Rhode Islandon file to place this against a meaningful peer group, so we don't.
Other addiction medicine in Lincoln
- Joseph RodgersProvidence$390
- Matthew RogalskiWoonsocket$261
- Michael CoburnNorth Kingstown$189
- Sylvester SvioklaWarwick$61
- Lily PikeProvidence$13
- Seth ClarkProvidence$12
- Caroline WunschProvidence$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.